Abstract：We expressed and purified the L1 major capsid protein of human papillomavirus type 16 (HPV16) in prokaryotic expression system and self-assemble virus like particles. Optimized HPV16 L1 gene according to the Escherichia coli cell codon in GenBank data base was truncated 25 mino acid residues at C-terminus and constructed pET28a-16L1△C25 expression vector. Ultrasound supernatant was purified by Ni-NTA affinity chromatography. Then the purified HPV16 L1 self-assemble into VLPs in vitro, we investigated the morphology of VLPs with dynamic light scattering and electronmicroscopy could assemble into VLPs, we used the purified VLPs to immunize BALB/c mice in 0, 2, 4 weeks and detected the titers of HPV16 specific neutralizing antibody in sera was detected by pseudovirus neutralization assay. HPV16 L1 we expressed in E. coli were major soluble forms analyzed by SDS-PAGE and western blotting. The soluble HPV16 L1 could self-assemble to VLPs in high efficiency, their shapes were similar to native HPV16 virions, The titer of HPV16 specific neutralizing antibody in sera was detected by pseudovirus neutralization assay at the sixth week,average value of Log10 was 4.43. The HPV16 VLPs prepared from prokaryotic expression system has the immunogenicity,which may provide a new way for research and development of low cost prophylactic HPV vaccine.
刘微, 郭明旸, 纪莉婷, 韩亚如, 谢文静, 王会岩. 人乳头瘤病毒16型L1的表达、病毒样颗粒组装及其免疫原性研究[J]. 中国人兽共患病学报, 2018, 34(8): 684-688.
LIU Wei, GUO Ming-yang, JI Li-ting, HAN Ya-ru, XIE Wen-jing, WANG Hui-yan. Expression of human papillomavirus type 16 L1 protein and assembly and immunization assessment of virus like particles. Chinese Journal of Zoonoses, 2018, 34(8): 684-688.
[1] Munger K, Baldwin A, Edwards KM, et al.Mechanisms of human papillomavirus-induced oncogenesis[J]. J Virol, 2004, 78(21): 11451-61140. DOI: 10.1128/JVI.78.21.11451-11460.2004 [2] Dell G.Human papillomaviruses and their role in cervical cancer[J].Cell Mol Life Sci, 2001, 58(12/13): 1923-1942. [3] Giroglou T,Sapp M,Lane C, et al.Immunological analyses of human papillomavirus capsids[J]. Vaccine,2001,19(13/14):1783-1793. [4] Zhang X,Li S,Modis Y, et al.Functional assessment and structural basis of antibody binding to human papillomavirus capsid[J]. Rev Med Virol, 2016,26(2):115-128. DOI: 10.1002/rmv.1867 [5] Stanley M.Immunobiology of HPV and HPV vaccines[J]. Gynecol Oncol,2008,109(2 Suppl):S15-21. DOI: 10.1016/j.ygyno. [6] Buck CB,Day PM,Trus BL, et al.The papillomavirus major capsid protein L1[J].Virology, 2013. 445(1/2):169-174. [7] Wang JW,Roden RB.L2, the minor capsid protein of papillomavirus[J]. Virology, 2013. 445(1/2) :175-186. DOI:10.1016/j.virol.2013.04.017 [8] Romanowski B.Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines[J]. Hum Vaccin,2011,7(2): 161-169. [9] Draper E.A randomized, observer-blinded immunogenicity trial of Cervarix(R) and Gardasil(R) Human Papillomavirus vaccines in 12-15 year old girls[J]. PloS one, 2013. 8(5):e61825. DOI:10.1371/journal.pone.0061825 [10] Gravitt PE, Winer RL.Natural history of HPV infection across the lifespan: role of viral latency[J]. Viruses, 2017, 9(10): E267. DOI:10.3390/v9100267 [11] Ogilvie G,Nakisige C,Huh WK,et al. Optimizing secondary prevention of cervical cancer: Recent advances and future challenges[J]. Int J Gynaecol Obstet.2017,138 Suppl 1:15-19. DOI:10.1002/ijgo.12187 [12] Ruiz W, Mcclements WL, Jansen KU, et al.Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant[J]. J Immune Based Ther Vacciness,2005, 3(1): 2. DOI:10.1186/1476-8518-3-2 [13] Villa LL, Costa RL, Petta CA, et al.High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up[J]. Br J Cancer,2006, 95(11): 1459-1466. DOI:10.1038/sj.bjc.6603469 [14] Harper DM, Franco EL, Wheeler C, et al.Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial[J]. Lancet, 2004, 364(9447): 1757-1765. DOI:10.1016/S0140-6736(04)17398-4 [15] Burgess-Brown NA,Sharma S,Sobott F,et al.Codon optimization can improve expression of human genes in Escherichia coli: a multi-genestudy[J]. Protein Expr Purif,2008,59(1):94-102. DOI:10.1016/j.pep.2008.01.008 [16] Chen XS,Garcea RL,Goldberg I, et al.Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16[J]. Mol Cell,2000,5(3):557-567. [17] Modis Y,Trus BL,Harrison SC.Atomic model of the papillomavirus capsid[J]. Eur Mol Biol Organ J,2002,21:4754-4762.
2018, Vol. 34 
